Product Description
Mechanisms of Action: 11beta-HSD1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Dominican Republic | Hong Kong | Hungary | India | Ireland | Malaysia | New Zealand | Peru | Philippines | Portugal | Spain | Taiwan | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: University Hospitals Birmingham NHS Trust
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2006-003426-28 | P2 |
Terminated |
Unknown |
2011-02-08 |